

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.*

(a joint stock limited company established in the People's Republic of China with limited liability)

(Stock Code: 8058)

NOTICE OF THE ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the “**Meeting**”) of members of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.* (the “**Company**”) will be held at Conference Room, Level 3, Administrative Centre, Luoqi Road, Linyi High and New Technology Industries Development Zone, Shandong Province, the People’s Republic of China (the “**PRC**”) on Wednesday, 22 June 2016 at 10:00 a.m. for the purposes of considering and, if thought fit, passing the following ordinary resolutions of the Company:

AS ORDINARY RESOLUTIONS

1. To consider and approve the audited financial statements of the Company and the reports of the board (the “**Board**”) of directors (the “**Directors**”) and the auditors of the Company for the year ended 31 December 2015;
2. to consider and approve the report of the supervisors of the Company for the year ended 31 December 2015;
3. to consider and approve a final dividend of RMB0.35 per share for the year ended 31 December 2015;
4. to consider and approve the Board to fix the remunerations of the Directors and supervisors of the Company;

* *For identification purpose only*

5. to consider and approve the appointment of HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration;
6. to re-elect Mr. Liu Bioqi (劉保起) as an executive Director;
7. to re-elect Ms. Li Minghua (李明華) as an executive Director;
8. to re-elect Mr. Han Fengsheng (韓風生) as an executive Director;
9. to re-elect Mr. Chen Yu (陳雨) as an executive Director;
10. to re-elect Mr. Liu Zhenteng (劉振騰) as an executive Director;
11. to re-elect Mr. Liu Zhenhai (劉振海) as a non-executive Director;
12. to re-elect Mr. Foo Tin Chung (傅天忠) as an independent non-executive Director;
13. to re-elect Mr. Fu Hongzheng (付宏征) as an independent non-executive Director;
14. to re-elect Prof. Du Guanhua (杜冠華) as an independent non-executive Director;
15. to appoint Ms. Huang Huiwen (黃慧文) as an independent non-executive Director;
16. to re-elect Mr. Wang Jian (王健) as a supervisor; and
17. to re-elect Mr. Liu Zhenfei (劉振飛) as a supervisor.

By order of the Board
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd*
Liu Baoqi
Chairman

PRC, 6 May 2016

* *For identification purpose only*

Registered Office:

Luoqi Road
Linyi High and New Technology
Industries Development Zone
Shandong Province, the PRC

Principal place of business in Hong Kong:

Unit 10, 11/F, Tower B, Southmark
11 Yip Hing Street
Wong Chuk Hang
Hong Kong

Notes:

1. Any shareholder who is entitled to attend and vote at the meeting may appoint one or more proxies to attend and vote at the meeting on his or her behalf. A proxy needs not be a member of the Company. A form of proxy for use at the meeting is enclosed herewith. In the case of joint holders of a share, any one of such joint holders may sign the form of proxy. If more than one of such joint holders attend the meeting either in person or by proxy, the vote of the joint holder whose name appears first in the register of members of the Company shall be accepted to the exclusion of the other joint holder(s).
2. In order to be valid, the proxy form and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at, in the case of a holder of H shares of the Company (the “**H Shares**”), the registrar of H Shares in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, and in the case of a holder of domestic shares of the Company (the “**Domestic Shares**”), the Company’s registered office at Luoqi Road, Linyi High and New Technology Industries Development Zone, Shandong Province, the PRC not less than 24 hours before the time for holding the meeting.
3. In order to determine the holders of H Shares who will be entitled to attend and vote at the AGM, the register of members of H Shares will be closed from Friday, 20 May 2016 to Wednesday, 22 June 2016 (both days inclusive). All properly completed H Shares transfer forms accompanied by the relevant share certificate must be lodged with the registrar for H Shares in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, no later than 4:30 p.m. on Thursday, 19 May 2016, for registration.

To determine Shareholders’ entitlement to the proposed final dividend, the registers of members of the Company will be closed from 28 June 2016 to 4 July 2016 (both days inclusive). All properly completed H-Shares transfer forms accompanied by the relevant share certificates must be lodged with the Registrar of H-Shares in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, no later than 4:30 p.m. on 27 June 2016, for registration.

4. Holders of Domestic Shares and H Shares whose names appear in the register of members at the close of business on Thursday, 19 May 2016 are entitled to attend and vote at the meeting.
5. Holders of Domestic Shares and H Shares who intend to attend the meeting shall complete and deposit or post or fax (fax no.: (86) 539 824 1226) the enclosed reply slip to the Company's registered office at Luoqi Road, Linyi High and New Technology Industries Development Zone, Shandong Province, the PRC on or before Thursday, 2 June 2016.
6. Holders of Domestic Shares and H Shares or their proxies shall produce their identity documents when attending the meeting.
7. Shareholders of the Company and proxies attending the meeting shall be responsible for their own transportation and accommodation expenses.

As at the date of this announcement, the Board comprises 11 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors, Mr. Yin Chuangui (尹傳貴) and Mr. Liu Zhenhai (劉振海) are non-executive Directors and Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Chen Yun Zhen (陳允震) and Prof. Du Guanhua (杜冠華) are independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company's designated website at: <http://shandongluoxin.quamir.com>.